We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BSAN:NEOBanco Santander S.A. Shs Sponsored Canadian Depository Receipt Hedged Reg S Analysis

Data as of 2026-03-11 - not real-time

CA$16.19

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The CDR trades at CAD 16.19, comfortably below its 20‑day (16.90) and 50‑day (17.04) simple moving averages, yet still above the 200‑day average (14.42), indicating a short‑term pull‑back within a longer‑term uptrend. Momentum is neutral with an RSI of 44 and a bearish MACD histogram (‑0.18) while volume has been dwindling, pushing the stock toward its near‑term support at 15.53 and away from resistance around 18.39. Volatility is elevated at roughly 49% over the past 30 days and beta is modest (≈0.68), suggesting price swings are pronounced but not overly correlated with broader markets. Fundamentally, the bank posts solid operating (43%) and profit margins (26%) and a respectable ROE of 13%, yet revenue is flat (‑0.5%) and the trailing P/E of 38.5 dwarfs the industry average of 17.1, flagging apparent overvaluation on earnings. Discounted cash‑flow analysis, however, yields a fair value of about 24.1, implying the current price is materially below intrinsic worth, while the extreme‑greed sentiment (78 on the Fear & Greed Index) may be inflating short‑term demand.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and decreasing volume signal limited upside
  • Price is near the technical support level of 15.53
  • High short‑term volatility (≈49%) adds price uncertainty

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Current price is well below DCF fair value of 24.09
  • Strong operating (43%) and profit margins (26%) support earnings stability
  • Price remains above the 200‑day SMA, indicating a longer‑term uptrend

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust profitability metrics (ROE 13%, operating margin 43%)
  • Undervalued relative to intrinsic DCF estimate despite high P/E
  • Diversified banking franchise with low beta reducing systematic risk

Key Metrics & Analysis

Financial Health

Revenue Growth-0.50%
Profit Margin25.87%
P/E Ratio38.5
ROE13.33%
ROA0.79%
P/B Ratio2.4
Op. Cash FlowCA$4.6B
Industry P/E17.1

Technical Analysis

TrendNeutral
RSI44.0
SupportCA$15.53
ResistanceCA$18.39
MA 20CA$16.90
MA 50CA$17.04
MA 200CA$14.42
MACDBearish
VolumeDecreasing
Fear & Greed Index78.16

Valuation

Fair ValueCA$24.09
GradeUndervalued
TypeValue

Risk Assessment

Beta0.68
Volatility49.05%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.